MA29272B1 - Derive de spirocetal et son utilisation comme medicament contre le diabete - Google Patents
Derive de spirocetal et son utilisation comme medicament contre le diabeteInfo
- Publication number
- MA29272B1 MA29272B1 MA30168A MA30168A MA29272B1 MA 29272 B1 MA29272 B1 MA 29272B1 MA 30168 A MA30168 A MA 30168A MA 30168 A MA30168 A MA 30168A MA 29272 B1 MA29272 B1 MA 29272B1
- Authority
- MA
- Morocco
- Prior art keywords
- substituted
- group
- compound
- possibly
- spirocetal
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 abstract 1
- 101000977048 Streptomyces cinnamonensis Uncharacterized protein in mutB 3'region Proteins 0.000 abstract 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Abstract
LA PRÉSENTE INVENTION A POUR OBJET UN COMPOSÉ DE FORMULE (I) SUIVANTE : [FORMULE CHIMIQUE 1] (I) (DANS LA FORMULE, R1, R2, R3 ET R4 REPRÉSENTENT INDÉPENDAMMENT UN ATOME D'HYDROGÈNE, UN GROUPEMENT ALKYLE EN C1-C6 ÉVENTUELLEMENT SUBSTITUÉ, UN GROUPEMENT ARYLALKYLE EN C7-C14 ÉVENTUELLEMENT SUBSTITUÉ, OU -C(=O)RX ; RX REPRÉSENTE UN GROUPEMENT ALKYLE EN C1-C6 ÉVENTUELLEMENT SUBSTITUÉ, UN GROUPEMENT ARYLE ÉVENTUELLEMENT SUBSTITUÉ, UN GROUPEMENT HÉTÉROARYLE ÉVENTUELLEMENT SUBSTITUÉ, UN GROUPEMENT ALCOXY EN C1-C6 ÉVENTUELLEMENT SUBSTITUÉ OU -NRERF ; AR1 REPRÉSENTE UN CYCLE HYDROCARBONÉ AROMATIQUE ÉVENTUELLEMENT SUBSTITUÉ OU UN HÉTÉROCYCLE AROMATIQUE ÉVENTUELLEMENT SUBSTITUÉ EN POSITION 1 ; Q REPRÉSENTE -(CH2)M-(L)P- OR -(L)P-(CH2)M- ; M REPRÉSENTE UN ENTIER COMPRIS ENTRE 0 ET 2 INCLUS ; N REPRÉSENTE 1 OU 2 ; P REPRÉSENTE 0 OU 1 ; L REPRÉSENTE -O-, -S- OU -NR5- ; ET A REPRÉSENTE UN GROUPEMENT ARYLE ÉVENTUELLEMENT SUBSTITUÉ OU UN GROUPEMENT HÉTÉROARYLE ÉVENTUELLEMENT SUBSTITUÉ.) LA PRÉSENTE INVENTION A ÉGALEMENT POUR OBJET UNE PRODROGUE D'UN TEL COMPOSÉ, UN SEL DE QUALITÉ PHARMACEUTIQUE DUDIT COMPOSÉ OU DE SA PRODROGUE, UN PRODUIT PHARMACEUTIQUE OU UNE PRÉPARATION PHARMACEUTIQUE CONTENANT UN TEL COMPOSÉ, ET SIMILAIRE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005020901 | 2005-01-28 | ||
JP2005176690 | 2005-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29272B1 true MA29272B1 (fr) | 2008-02-01 |
Family
ID=36740445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30168A MA29272B1 (fr) | 2005-01-28 | 2007-08-28 | Derive de spirocetal et son utilisation comme medicament contre le diabete |
Country Status (24)
Country | Link |
---|---|
US (1) | US7767651B2 (fr) |
EP (2) | EP3072897B1 (fr) |
JP (1) | JP4093587B2 (fr) |
KR (2) | KR20130102648A (fr) |
AR (1) | AR054612A1 (fr) |
AU (1) | AU2006209523B2 (fr) |
BR (1) | BRPI0606367B1 (fr) |
CA (1) | CA2596235C (fr) |
CR (1) | CR9314A (fr) |
DK (1) | DK1852439T3 (fr) |
ES (1) | ES2567439T3 (fr) |
HK (1) | HK1111999A1 (fr) |
HR (1) | HRP20160333T1 (fr) |
HU (1) | HUE027078T2 (fr) |
IL (1) | IL184838A (fr) |
MA (1) | MA29272B1 (fr) |
MY (1) | MY140528A (fr) |
NO (1) | NO341263B1 (fr) |
NZ (1) | NZ556343A (fr) |
PL (1) | PL1852439T3 (fr) |
RU (1) | RU2416617C2 (fr) |
SI (1) | SI1852439T1 (fr) |
TW (1) | TW200637869A (fr) |
WO (1) | WO2006080421A1 (fr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI335218B (en) * | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP2019679B1 (fr) * | 2006-05-23 | 2018-06-20 | Theracos, Inc. | Inhibiteurs de transport de glucose et procédés d'utilisation |
TWI403516B (zh) * | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
TWI432446B (zh) * | 2006-07-27 | 2014-04-01 | Chugai Pharmaceutical Co Ltd | 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用 |
EP2072522A4 (fr) * | 2006-10-13 | 2010-01-06 | Chugai Pharmaceutical Co Ltd | Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète |
US7795228B2 (en) | 2006-12-28 | 2010-09-14 | Theracos, Inc. | Spiroheterocyclic glycosides and methods of use |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
LT2187742T (lt) * | 2007-08-23 | 2018-01-10 | Theracos Sub, Llc | (2s,3r,4r,5s,6r)-2-(4-chlor-3-benzilfenil)-6-(hidroksimetil)tetrahidro-2h-piran-3,4,5-triolio dariniai, skirti panaudoti diabeto gydymui |
UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
JP5820269B2 (ja) | 2008-05-22 | 2015-11-24 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | Sglt2阻害剤を使用する高尿酸血症の治療方法およびsglt2阻害剤を含有する組成物 |
TW201011043A (en) | 2008-06-20 | 2010-03-16 | Chugai Pharmaceutical Co Ltd | Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives |
NZ604897A (en) | 2008-08-22 | 2014-03-28 | Theracos Sub Llc | Processes for the preparation of sglt2 inhibitors |
AP2728A (en) * | 2008-08-28 | 2013-08-31 | Pfizer | Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives |
JP5685550B2 (ja) | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Sglt2阻害剤、dpp−iv阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
JP5696156B2 (ja) | 2009-11-02 | 2015-04-08 | ファイザー・インク | ジオキサ−ビシクロ[3.2.1]オクタン−2,3,4−トリオール誘導体 |
CN102656177B (zh) * | 2009-12-18 | 2016-01-27 | 中外制药株式会社 | 螺酮缩醇衍生物的制备方法 |
BR112012025592A2 (pt) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos |
WO2011153712A1 (fr) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012041898A1 (fr) | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète |
WO2012115249A1 (fr) * | 2011-02-25 | 2012-08-30 | 中外製薬株式会社 | Cristal de dérivé de spirocétal |
UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (fr) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012170702A1 (fr) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci |
WO2013055910A1 (fr) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
TW201400495A (zh) * | 2012-04-03 | 2014-01-01 | Daiichi Sankyo Co Ltd | 具有螺環之c-醣苷衍生物 |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
WO2014074668A1 (fr) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulateurs de gpr119 et traitement de troubles associés à ceux-ci |
WO2015051484A1 (fr) | 2013-10-12 | 2015-04-16 | Theracos, Inc. | Préparation de dérivés d'hydroxy-benzylbenzène |
EP3482748A1 (fr) * | 2013-12-27 | 2019-05-15 | Chugai Seiyaku Kabushiki Kaisha | Préparations solides comprenant de la tofogliflozine et procédé de production associé |
US10346562B2 (en) * | 2014-08-21 | 2019-07-09 | Dassault Systèmes Canada Inc. | Automated curvature modeling of polygonal lines |
CN106317068A (zh) * | 2015-06-23 | 2017-01-11 | 中国科学院上海药物研究所 | 一种c,o-螺环芳基糖苷类化合物及其制备和应用 |
EA201990951A1 (ru) | 2016-10-19 | 2019-11-29 | Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение | |
CA3047716A1 (fr) | 2017-01-11 | 2018-07-19 | Kowa Company, Ltd. | Medicament pour la prevention et le traitement de steatose hepatique non alcoolique |
EP3781166A1 (fr) | 2018-04-17 | 2021-02-24 | Boehringer Ingelheim International GmbH | Composition pharmaceutique, méthodes de traitement et utilisations associées |
BR112021000139A2 (pt) | 2018-07-19 | 2021-04-06 | Astrazeneca Ab | Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma |
WO2020039394A1 (fr) | 2018-08-24 | 2020-02-27 | Novartis Ag | Nouvelles combinaisons de médicaments |
AU2021230562A1 (en) | 2020-03-06 | 2022-09-22 | Vertex Pharmaceuticals Incorporated | Methods of treating APOL-1 dependent focal segmental glomerulosclerosis |
US20220023252A1 (en) | 2020-07-27 | 2022-01-27 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
AU2022251165A1 (en) | 2021-04-01 | 2023-11-09 | Astrazeneca Uk Limited | Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition |
WO2023144722A1 (fr) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozine destinée à être utilisée dans le traitement du prédiabète ou pour réduire le risque de développer un diabète de type 2 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5470845A (en) | 1992-10-28 | 1995-11-28 | Bristol-Myers Squibb Company | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia |
JP2762903B2 (ja) | 1992-11-12 | 1998-06-11 | 田辺製薬株式会社 | ジヒドロカルコン誘導体及びその製法 |
CA2102591C (fr) | 1992-11-12 | 2000-12-26 | Kenji Tsujihara | Agent hypoglycemiant |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
JP2814950B2 (ja) | 1994-05-11 | 1998-10-27 | 田辺製薬株式会社 | 血糖降下剤 |
US5830873A (en) | 1994-05-11 | 1998-11-03 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and a process for preparing the same |
JP3065235B2 (ja) | 1995-11-07 | 2000-07-17 | 田辺製薬株式会社 | プロピオフェノン誘導体およびその製法 |
JP3006513B2 (ja) | 1995-11-07 | 2000-02-07 | 田辺製薬株式会社 | 医薬組成物 |
JP3034192B2 (ja) | 1995-11-07 | 2000-04-17 | 田辺製薬株式会社 | プロピオフェノン誘導体およびその製法 |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
PT850948E (pt) | 1996-12-26 | 2002-08-30 | Tanabe Seiyaku Co | Derivados propiofenona e processo para a preparacao dos mesmos |
JP3055135B2 (ja) | 1996-12-26 | 2000-06-26 | 田辺製薬株式会社 | プロピオフェノン誘導体及びその製法 |
JP2000080041A (ja) | 1998-03-09 | 2000-03-21 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
ATE264337T1 (de) | 1999-08-31 | 2004-04-15 | Kissei Pharmaceutical | Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung |
US6284906B1 (en) * | 1999-10-12 | 2001-09-04 | University Of Southern California | Cyclotrisiloxanes, new siloxane polymers and their preparation |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6627611B2 (en) | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
NZ521369A (en) | 2000-03-17 | 2004-07-30 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
CZ303544B6 (cs) | 2000-09-29 | 2012-11-28 | Kissei Pharmaceutical Co., Ltd. | Glukopyranosyloxybenzylbenzenový derivát a farmaceutická kompozice s jeho obsahem |
AU2002210990A1 (en) | 2000-11-02 | 2002-05-15 | Ajinomoto Co. Inc. | Novel pyrazole derivatives and diabetes remedies containing the same |
CA2429833A1 (fr) | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions |
PL209375B1 (pl) | 2000-12-28 | 2011-08-31 | Kissei Pharmaceutical | Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna zawierająca takie pochodne i zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej |
TWI255817B (en) | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
EP1364957B1 (fr) | 2001-02-26 | 2008-12-31 | Kissei Pharmaceutical Co., Ltd. | Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci |
US7294618B2 (en) | 2001-02-27 | 2007-11-13 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
ATE318272T1 (de) | 2001-04-11 | 2006-03-15 | Bristol Myers Squibb Co | Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren |
EP1389621A4 (fr) | 2001-04-27 | 2005-05-11 | Ajinomoto Kk | Derives pyrazolyl-o-glycoside n-substitues et medicament contre le diabete en contenant |
CA2448741C (fr) | 2001-05-30 | 2010-06-22 | Kissei Pharmaceutical Co., Ltd. | Derive de glucopyranosyloxypyrazole, composition medicinale contenant celui-ci, et utilisation medicinale et intermediaire de celui-ci |
EP1405859A4 (fr) | 2001-06-20 | 2008-01-23 | Kissei Pharmaceutical | Derive heterocyclique azote, composition medicinale contenant ce derive, leur utilisation medicinale et intermediaire associe |
JP4115105B2 (ja) | 2001-07-02 | 2008-07-09 | 協和醗酵工業株式会社 | ピラゾール誘導体 |
WO2003011880A1 (fr) | 2001-07-31 | 2003-02-13 | Kissei Pharmaceutical Co., Ltd. | Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition |
WO2003020737A1 (fr) | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | Inhibiteurs de sglt2 contenant du glucoside de o-pyrazole et methode d'utilisation |
WO2003090783A1 (fr) | 2002-04-26 | 2003-11-06 | Ajinomoto Co., Inc. | Agent preventif/remede pour diabete |
DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
TWI254635B (en) | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
AU2003254904A1 (en) | 2002-08-09 | 2004-02-25 | Taisho Pharmaceutical Co., Ltd. | Aryl 5-thio-beta-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same |
DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10258008B4 (de) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
US7655633B2 (en) | 2002-12-25 | 2010-02-02 | Kissei Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof |
CN101260130A (zh) | 2003-01-03 | 2008-09-10 | 布里斯托尔-迈尔斯斯奎布公司 | 制备c-芳基葡糖苷sglt2抑制剂的方法 |
MXPA05009356A (es) | 2003-03-14 | 2005-12-05 | Astellas Pharma Inc | Derivados de c-glicosido y sales de los mismos. |
JP2004300102A (ja) | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
WO2004089967A1 (fr) | 2003-04-01 | 2004-10-21 | Taisho Pharmaceutical Co., Ltd. | Derives heteroaryle 5-thio-$g(b)-d-glucopyranoside et medicaments contre le diabete contenant ces derives |
AU2003902263A0 (en) | 2003-05-12 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
JP2004359630A (ja) | 2003-06-06 | 2004-12-24 | Yamanouchi Pharmaceut Co Ltd | ジフルオロジフェニルメタン誘導体及びその塩 |
EP1637539B1 (fr) | 2003-06-20 | 2012-01-18 | Kissei Pharmaceutical Co., Ltd. | Derive de pyrazole, composition de medicaments contenant ledit derive et intermediaire de production associe |
AR048377A1 (es) | 2003-08-01 | 2006-04-26 | Janssen Pharmaceutica Nv | Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos |
SG130189A1 (en) | 2003-08-01 | 2007-03-20 | Janssen Pharmaceutica Nv | Substituted indole-o-glucosides |
UA86042C2 (en) | 2003-08-01 | 2009-03-25 | Янссен Фармацевтика Н.В. | Substituted indazole-o-glucosides |
RS20060320A (en) | 2003-08-01 | 2008-08-07 | Janssen Pharmaceutica N.V., | Substituted indazole-o-glucosides |
EA015104B1 (ru) | 2003-08-01 | 2011-06-30 | Мицубиси Танабе Фарма Корпорейшн | Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера |
EA009768B1 (ru) | 2003-08-01 | 2008-04-28 | Янссен Фармацевтика Нв | Замещенные конденсированные гетероциклические с-гликозиды |
CA2539032A1 (fr) | 2003-08-26 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Pyrazoles glucopyranosyloxy, medicaments contenant ces composes, leur utilisation et leur procede de production |
US8258105B2 (en) | 2003-10-07 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides optimized for kidney targeting |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
DE10361133A1 (de) | 2003-12-22 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
JP2005247834A (ja) | 2004-02-04 | 2005-09-15 | Taisho Pharmaceut Co Ltd | ナトリウム依存性グルコース供輸送体2の活性阻害剤 |
CN1950389B (zh) | 2004-03-04 | 2011-01-19 | 橘生药品工业株式会社 | 含氮稠环衍生物,含该衍生物的药物组合物,和其作为药物的用途 |
AU2005219779B2 (en) | 2004-03-04 | 2011-04-14 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
WO2005085265A1 (fr) | 2004-03-04 | 2005-09-15 | Kissei Pharmaceutical Co., Ltd. | Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse |
RS52365B (en) | 2004-03-16 | 2012-12-31 | Boehringer Ingelheim International Gmbh | BENZOL DERIVATIVES SUBSTITUTED BY GLUCOPYRANOSIL, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, THEIR USE AND THE PROCEDURE FOR THEIR PRODUCTION |
WO2005095373A1 (fr) | 2004-03-31 | 2005-10-13 | Kissei Pharmaceutical Co., Ltd. | Dérivé naphtalénique, composition médicale le contenant et usage médical |
JPWO2005095372A1 (ja) | 2004-03-31 | 2008-02-21 | キッセイ薬品工業株式会社 | ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途 |
JPWO2005095429A1 (ja) | 2004-03-31 | 2008-02-21 | キッセイ薬品工業株式会社 | フェノール誘導体、それを含有する医薬組成物及びその医薬用途 |
DE102004028241B4 (de) | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
-
2006
- 2006-01-25 TW TW095102876A patent/TW200637869A/zh unknown
- 2006-01-26 MY MYPI20060375A patent/MY140528A/en unknown
- 2006-01-27 KR KR1020137020138A patent/KR20130102648A/ko not_active Application Discontinuation
- 2006-01-27 AU AU2006209523A patent/AU2006209523B2/en active Active
- 2006-01-27 KR KR1020077019678A patent/KR101322980B1/ko active IP Right Grant
- 2006-01-27 NZ NZ556343A patent/NZ556343A/en unknown
- 2006-01-27 AR ARP060100301A patent/AR054612A1/es not_active Application Discontinuation
- 2006-01-27 DK DK06712450.3T patent/DK1852439T3/en active
- 2006-01-27 ES ES06712450.3T patent/ES2567439T3/es active Active
- 2006-01-27 US US11/815,074 patent/US7767651B2/en active Active
- 2006-01-27 WO PCT/JP2006/301284 patent/WO2006080421A1/fr active Application Filing
- 2006-01-27 HU HUE06712450A patent/HUE027078T2/en unknown
- 2006-01-27 JP JP2007500586A patent/JP4093587B2/ja active Active
- 2006-01-27 CA CA2596235A patent/CA2596235C/fr active Active
- 2006-01-27 BR BRPI0606367-5A patent/BRPI0606367B1/pt active IP Right Grant
- 2006-01-27 SI SI200632049A patent/SI1852439T1/sl unknown
- 2006-01-27 PL PL06712450.3T patent/PL1852439T3/pl unknown
- 2006-01-27 EP EP16161071.2A patent/EP3072897B1/fr active Active
- 2006-01-27 RU RU2007132448/04A patent/RU2416617C2/ru active
- 2006-01-27 EP EP06712450.3A patent/EP1852439B1/fr active Active
-
2007
- 2007-07-25 IL IL184838A patent/IL184838A/en active IP Right Grant
- 2007-08-15 CR CR9314A patent/CR9314A/es unknown
- 2007-08-23 NO NO20074310A patent/NO341263B1/no unknown
- 2007-08-28 MA MA30168A patent/MA29272B1/fr unknown
-
2008
- 2008-06-24 HK HK08107008.7A patent/HK1111999A1/xx unknown
-
2016
- 2016-04-04 HR HRP20160333TT patent/HRP20160333T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29272B1 (fr) | Derive de spirocetal et son utilisation comme medicament contre le diabete | |
NO20053211L (no) | Forbindelser for behandling av metabolske forstyrrelser. | |
MA30483B1 (fr) | Utilisation de biphenylamides d'acide arylcarboxylique pour le traitement de semences. | |
CA2394086A1 (fr) | Derives de 4-aminopiperidine et leur utilisation en tant que medicament | |
TW369535B (en) | A pyrazolopyridine compound and the process for preparing thereof | |
WO2009068531A3 (fr) | Composés organiques | |
CA2336412A1 (fr) | Medicament pour le traitement du diabete | |
HUP0203431A2 (hu) | Új heterociklusos vegyületek és sóik, és ezeket tartalmazó gyógyszerkészítmények, valamint felhasználásuk | |
MA30767B1 (fr) | Composes azabicycliques en tant qu'inhibiteurs de reabsorption de monoamines | |
MA31359B1 (fr) | Pyrimidinyl-pipérazines utiles en tant que ligands des récepteurs d3/d2 | |
RU94037246A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща | |
MA31861B1 (fr) | Composés fongicides, procédé pour leur préparation et leur utilisation pour lutter contre des champignons nuisibles ainsi qu'agents les contenant | |
HUP0200121A2 (hu) | Kalcilitikus vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
UA91645C2 (ru) | Соединения индола, способ их получения и фармацевтическая композиция (варианты), которая их содержит | |
TW200616679A (en) | Modified-release preparation | |
DE602007010041D1 (de) | Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs | |
UA90290C2 (ru) | Производные спирокеталов и их применение в качестве лекарственного средства против диабета | |
MA28325A1 (fr) | Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
UA81610C2 (ru) | Изохинолиновые соединения, способ их получения и фармацевтическая композиция, которая их содержит | |
UA91646C2 (ru) | Соединения индола, способ их получения и фармацевтическая композиция (варианты), которая их содержит | |
JPS6270335A (ja) | 2環性アリルエ−テル誘導体、その製法および用途 | |
MA30463B1 (fr) | 3-(pyridine-2-yl)-[1,2,4]-triazines utilisees comme fongicides. | |
TW200503697A (en) | Medicinal compositions containing triazole compounds | |
WO2005025492A3 (fr) | Nouvelles compositions, compositions pharmaceutiques, et methodes de traitement et de prevention d'une cardiopathie | |
MA30068B1 (fr) | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |